Trust Co. of Vermont Cuts Stake in Laboratory Co. of America Holdings (NYSE:LH)

Trust Co. of Vermont lessened its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 3.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,465 shares of the medical research company’s stock after selling 86 shares during the quarter. Trust Co. of Vermont’s holdings in Laboratory Co. of America were worth $565,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Meiji Yasuda Asset Management Co Ltd. boosted its holdings in Laboratory Co. of America by 4.9% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 1,284 shares of the medical research company’s stock worth $261,000 after acquiring an additional 60 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of Laboratory Co. of America by 28.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,684 shares of the medical research company’s stock valued at $1,564,000 after purchasing an additional 1,680 shares during the last quarter. XTX Topco Ltd raised its position in shares of Laboratory Co. of America by 13.0% in the 2nd quarter. XTX Topco Ltd now owns 6,282 shares of the medical research company’s stock valued at $1,278,000 after purchasing an additional 722 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Laboratory Co. of America in the 2nd quarter worth approximately $987,000. Finally, Brighton Jones LLC grew its position in Laboratory Co. of America by 83.9% during the 2nd quarter. Brighton Jones LLC now owns 4,261 shares of the medical research company’s stock worth $867,000 after purchasing an additional 1,944 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insider Transactions at Laboratory Co. of America

In other Laboratory Co. of America news, CMO Amy B. Summy sold 3,672 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $238.91, for a total transaction of $877,277.52. Following the completion of the sale, the chief marketing officer now directly owns 4,318 shares in the company, valued at approximately $1,031,613.38. The trade was a 45.96 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kerrii B. Anderson sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the transaction, the director now owns 13,722 shares in the company, valued at approximately $3,156,060. This trade represents a 6.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 25,572 shares of company stock valued at $6,145,209 in the last three months. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Stock Performance

LH opened at $238.44 on Friday. The stock has a market cap of $19.94 billion, a P/E ratio of 46.12, a P/E/G ratio of 1.73 and a beta of 1.06. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The firm has a fifty day moving average price of $234.80 and a 200 day moving average price of $225.76. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $247.99.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.02. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The business had revenue of $3.28 billion during the quarter, compared to the consensus estimate of $3.26 billion. During the same quarter in the prior year, the firm posted $3.38 earnings per share. The company’s revenue was up 7.4% compared to the same quarter last year. Equities research analysts anticipate that Laboratory Co. of America Holdings will post 14.51 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.21%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. HSBC raised shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Wednesday, October 30th. StockNews.com cut Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Hsbc Global Res upgraded Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 30th. Evercore ISI upgraded Laboratory Co. of America from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $260.00 to $265.00 in a research note on Tuesday, January 7th. Finally, Piper Sandler upped their target price on Laboratory Co. of America from $235.00 to $240.00 and gave the company a “neutral” rating in a research report on Monday, October 28th. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $260.54.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.